Multivariate analysis of severe neutropenia and neutrophil recovery during the post–CAR-T period
| Characteristic . | Severe neutropenia, early post–CAR-T period, n = 129 (106 events) . | Severe neutropenia, late post–CAR-T period n = 114 (50 events) . | Time to neutrophil recovery, n = 108 (83 events) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Age, y (cont.) | 1.02 | 0.95-1.08 | .63 | 0.99 | 0.94-1.03 | .56 | 1 | 0.98-1.03 | .91 |
| Sex, female | 2.45 | 0.78-9.07 | .15 | 1.53 | 0.66-3.60 | .33 | 0.82 | 0.50-1.35 | .44 |
| Center, United States | 0.77 | 0.09-17.1 | .83 | 1.11 | 0.20-5.85 | .9 | 0.91 | 0.33-2.50 | .86 |
| Previous therapy lines, greater than the median (>5): yes | 0.69 | 0.24-1.96 | .49 | 1.86 | 0.83-4.23 | .13 | 0.73 | 0.45-1.16 | .18 |
| G-CSF prophylaxis, yes | 0.25 | 0.01-1.96 | .24 | 0.81 | 0.15-4.63 | .81 | 0.91 | 0.30-2.75 | .86 |
| PD before LD, yes | 1.93 | 0.68-5.81 | .22 | 2.33 | 1.02-5.52 | .048 | 0.42 | 0.24-0.71 | .001 |
| Grade ≥3 neutropenia, thrombocytopenia, and/or anemia before LD: yes | 4.72 | 0.66-98.5 | .18 | 1.02 | 0.28-3.68 | .98 | 1.21 | 0.62-2.39 | .58 |
| CRS grade ≥2, yes | 4.67 | 1.30-22.9 | .031 | 2.49 | 1.03-6.20 | .045 | 0.89 | 0.55-1.44 | .65 |
| BT: intensive CTX, yes | 2.17 | 0.44-16.4 | .38 | 3.52 | 0.92-15.1 | .073 | 0.36 | 0.17-0.78 | .01 |
| Characteristic . | Severe neutropenia, early post–CAR-T period, n = 129 (106 events) . | Severe neutropenia, late post–CAR-T period n = 114 (50 events) . | Time to neutrophil recovery, n = 108 (83 events) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | OR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Age, y (cont.) | 1.02 | 0.95-1.08 | .63 | 0.99 | 0.94-1.03 | .56 | 1 | 0.98-1.03 | .91 |
| Sex, female | 2.45 | 0.78-9.07 | .15 | 1.53 | 0.66-3.60 | .33 | 0.82 | 0.50-1.35 | .44 |
| Center, United States | 0.77 | 0.09-17.1 | .83 | 1.11 | 0.20-5.85 | .9 | 0.91 | 0.33-2.50 | .86 |
| Previous therapy lines, greater than the median (>5): yes | 0.69 | 0.24-1.96 | .49 | 1.86 | 0.83-4.23 | .13 | 0.73 | 0.45-1.16 | .18 |
| G-CSF prophylaxis, yes | 0.25 | 0.01-1.96 | .24 | 0.81 | 0.15-4.63 | .81 | 0.91 | 0.30-2.75 | .86 |
| PD before LD, yes | 1.93 | 0.68-5.81 | .22 | 2.33 | 1.02-5.52 | .048 | 0.42 | 0.24-0.71 | .001 |
| Grade ≥3 neutropenia, thrombocytopenia, and/or anemia before LD: yes | 4.72 | 0.66-98.5 | .18 | 1.02 | 0.28-3.68 | .98 | 1.21 | 0.62-2.39 | .58 |
| CRS grade ≥2, yes | 4.67 | 1.30-22.9 | .031 | 2.49 | 1.03-6.20 | .045 | 0.89 | 0.55-1.44 | .65 |
| BT: intensive CTX, yes | 2.17 | 0.44-16.4 | .38 | 3.52 | 0.92-15.1 | .073 | 0.36 | 0.17-0.78 | .01 |
Significant P values are set in boldface.
BT, bridging therapy; cont., continuous; G-CSF, granulocyte-colony stimulating factor; LD, lymphodepletion; PD, progressive disease.